Five Prime Therapeutics Announces Fourth Quarter and Full

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Five Prime Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results

SOUTH SAN FRANCISCO, Calif., March 17, 2015 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq: FPRX ), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2014.

"2014 was a remarkable year for Five Prime," said Lewis T. "Rusty" Williams, M.D., Ph.D., Founder and Chief Executive Officer of Five Prime. "We began the year with two candidates in the clinic and our pipeline has now grown to three clinical-stage therapeutics covering 11 indications. We have substantially broadened our presence in immuno-oncology through a new clinical collaboration with Bristol-Myers Squibb in which we are expanding development of FPA008, our CSF1 receptor antibody, into multiple tumor types in combination with nivolumab. Five Prime is also initiating development of FPA008 in pigmented villonodular synovitis (PVNS), a tumor driven by the CSF1 receptor pathway. Finally, we've initiated a Phase 1 trial for our newest clinical candidate, FPA144. This FGF receptor 2b antibody will be developed for a subset of patients with gastric cancer, an indication with a high unmet need and a focused development path. As I look ahead, I am excited that we have the team and resources to advance each of our clinical programs as well as our discovery work in immuno-oncology."

Business Highlights and Recent Developments

Pipeline:

  • FPA008: FPA008 targets monocytes and macrophages, which are elevated or activated in multiple disease settings. In cancer, macrophages suppress the immune system's ability to kill cancer cells. In joint diseases, such as PVNS and RA, macrophages play a central role in the disease process.
    • Reported Healthy Volunteer Data from Phase 1 Clinical Trial of FPA008. Five Prime presented data from the healthy volunteer cohorts of its Phase 1 trial of FPA008 during the 2014 American College of Rheumatology (ACR) Annual Scientific Meeting. FPA008 was well tolerated at doses up to 3 mg/kg and showed modulation of key biomarkers that may indicate the potential for clinical benefit. Additionally, pharmacokinetic data supported dosing intervals of two weeks or more. The safety profile supports the exploration of FPA008 in a variety of indications, including as part of combination therapy regimens.
    • Announced Immuno-Oncology Clinical Trial Collaboration with Bristol-Myers Squibb (BMS) for FPA008. Five Prime and BMS entered into a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of combining FPA008 with nivolumab, BMS's PD-1 immune checkpoint antibody. Five Prime and BMS plan to explore the combination in patients with non-small cell lung cancer, melanoma, head and neck cancer, pancreatic cancer, colorectal cancer and malignant glioma. Five Prime expects the Phase 1a/1b trial to begin by mid-2015.
    • Began Preparations for a Phase 1/2 Clinical Trial of FPA008 in PVNS. Five Prime plans to begin a Phase 1/2 clinical trial of FPA008 in PVNS, an orphan indication, by mid-2015. The Company anticipates that preliminary efficacy data from the Phase 1 portion of this trial could be available by the end of 2015 or early 2016.
    • Initiated Dosing in Rheumatoid Arthritis (RA) Patients in Phase 1 Clinical Trial of FPA008. Five Prime began dosing FPA008 in RA patients with active disease who are on methotrexate in part 3 of its Phase 1 clinical trial. Five Prime plans to report preliminary open-label data in RA patients by the end of 2015.
  • Initiated Patient Dosing in the Phase 1 Clinical Trial of FPA144 . Five Prime initiated dosing in its Phase 1a/1b clinical trial of FPA144. The trial is initially enrolling unselected patients with solid tumors and will subsequently enroll selected gastric cancer patients with FGFR2b protein overexpression or FGFR2 gene amplification in their tumors as identified through molecular diagnostic assays. By the end of 2015, Five Prime expects to complete the dose escalation portion of the trial, begin expansion in gastric cancer patients, and report preliminary safety data from the study.
  • Continued Enrollment in the Phase 1b Clinical Trial of FP-1039/GSK3052230, an FGF Ligand Trap, in Non-Small Cell Lung Cancer and Mesothelioma. GlaxoSmithKline (GSK) completed dose escalation in one of the three arms and began expansion in that arm. Arms A and B continue to enroll patients with newly-diagnosed or recurrent squamous non-small cell lung cancer (NSCLC) whose tumors have amplification of the FGF receptor 1 gene. Arm C is enrolling patients with malignant pleural mesothelioma. GSK plans to present preliminary data at a scientific meeting by the end of 2015.

Internal Research:

  • Progressed Internal Immuno-Oncology Research Program . During 2014, Five Prime dedicated additional personnel and resources to expand the breadth and depth of its internal immuno-oncology program, which has led to the identification of promising antibody targets and ligand traps. Five Prime also presented a poster at the 2014 Society for Immunotherapy of Cancer Annual Meeting describing the use of the Company's target discovery platform to identify unique immuno-oncology targets.

Discovery Collaborations:

  • Entered into Collaboration Agreement with BMS. In March 2014, Five Prime entered into a collaboration agreement with BMS for the discovery, development and commercialization of immuno-oncology therapies directed toward targets identified in two undisclosed immune checkpoint pathways using Five Prime's proprietary target discovery platform. Five Prime is free to pursue all other pathways in immuno-oncology outside of the collaboration.
  • Expanded Respiratory Diseases Collaboration with GSK. In October 2014, Five Prime announced the expansion of its respiratory diseases research collaboration with GSK. The scope of the collaboration was broadened and includes two additional respiratory disease screening assays.
  • Licensed Target in GSK Muscle Diseases Collaboration. In September 2014, GSK took a commercial license to an undisclosed muscle disease target that Five Prime identified using the company's proprietary target discovery platform.

Finance:

  • Completed February 2014 Public Offering of Common Stock. In February 2014, Five Prime completed an underwritten public offering of common stock, raising net proceeds of $40.1 million.
  • Completed January 2015 Public Offering of Common Stock . In January 2015, Five Prime completed an underwritten public offering of common stock, raising net proceeds of $78.7 million.

Summary of Financial Results and Guidance:

  • Cash Position. Cash, cash equivalents and marketable securities totaled $149.1 million on December 31, 2014 compared to $75.7 million on December 31, 2013. This does not include the proceeds from the January 2015 public offering of common stock. The increase in year end 2014 cash was primarily attributable to Five Prime's public offering of common stock in February 2014, BMS's purchase of $21.0 million of common stock in March 2014, the $20.0 million upfront payment received from BMS for the immuno-oncology research collaboration and the $30.0 million one-time fee received from BMS for the immuno-oncology clinical collaboration offset by cash used in operations.
  • Revenue. Collaboration revenue for the fourth quarter of 2014 increased by $0.8 million, or 21%, to $4.6 million from $3.8 million in the fourth quarter of 2013, primarily due to revenue recognized under the immuno-oncology research collaboration with BMS. Collaboration revenue for the full year 2014 increased by $5.4 million, or 39%, to $19.2 million in 2014 from $13.8 million in 2013 primarily due to revenue recognized under our collaborations with UCB, GSK, and BMS.
  • R&D Expenses. Research and development expenses for the fourth quarter of 2014 increased by $4.5 million, or 56%, to $12.6 million from $8.1 million in the fourth quarter of 2013. Full year 2014 research and development expenses increased by $10.4 million, or 32%, to $43.2 million in 2014 from $32.8 million in 2013. This increase was primarily related to advancing the FPA144 program into a Phase 1 clinical trial and expanding our internal immuno-oncology research.
  • G&A Expenses. General and administrative expenses for the fourth quarter of 2014 increased by $1.0 million, or 33%, to $4.0 million from $3.0 million in the fourth quarter of 2013. Full year 2014 general and administrative expenses were $13.6 million, an increase of $3.2 million, or 31%, from $10.4 million in 2013. This increase was primarily due to increased public company related expenses, and increases in non-cash stock based compensation and cash compensation.
  • Net Loss. Net loss for the fourth quarter of 2014 was $11.8 million, or $0.55 per basic and diluted share, compared to a net loss of $7.3 million, or $0.43 per basic and diluted share, for the fourth quarter of 2013. Full year 2014 net loss was $37.4 million, or $1.79 per basic and diluted share, compared to a net loss of $28.9 million, or $5.23 per basic and diluted share. This increase in net loss was primarily related to advancing the FPA144 program into a phase 1 clinical trial and expanding internal immuno-oncology discovery efforts.

Cash Guidance. Five Prime expects full year 2015 net cash used in operating activities to be less than $65 million and estimates ending 2015 with more than $160 million in cash, cash equivalents and marketable securities. Five Prime expects to have cash to fund operations into the first half of 2018, without entering into any additional collaboration agreements or receiving any future milestone payments. This provides runway through efficacy data milestones for all current clinical programs.

Conference Call Information

Five Prime will host a conference call and live audio webcast today at 5 p.m. (ET) / 2 p.m. (PT) to discuss its financial results and provide a corporate update. To participate in the conference call, please dial (877) 878-2269 (domestic) or (253) 237-1188 (international) and refer to conference ID 94614642. To access the live webcast please visit the "Events & Presentations" page under the "Investors" tab on Five Prime's website at www.fiveprime.com .

An archived copy of the webcast will be available on Five Prime's website beginning approximately two hours after the conference call. Five Prime will maintain an archived replay of the webcast on its website for at least 30 days after the conference call.

About Five Prime

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit www.fiveprime.com .

Cautionary Note on Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Five Prime's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements about (i) the timing of initiation, progress and scope of clinical trials for Five Prime's product candidates; (ii) the reporting of clinical results regarding Five Prime's product candidates; (iii) Five Prime's full-year 2015 net cash used in operating activities; (iv) the amount of Five Prime's cash, cash equivalents and marketable securities at the end of 2015; and (v) the period during which FivePrime expects to be able to fund operations. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of Five Prime's collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Other factors that may cause Five Prime's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Five Prime's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Five Prime assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

     
Five Prime Therapeutics, Inc.
Selected Balance Sheets Data
(in thousands)
     
  As of December 31,
  2014 2013
Balance Sheet Data:    
Cash, cash equivalents and marketable securities $ 149,054 $ 75,722
Total assets 155,631 81,791
Total current liabilities (excluding deferred revenue) 7,877 5,910
Deferred revenue (in total, including short term portion) 60,566 15,036
Total stockholders' equity 85,205 58,026
     
         
Five Prime Therapeutics, Inc.
Condensed Statements of Operations
(In Thousands Except Per Share Amounts)
         
  For the Three Months For the Year
  Ended Ended
  December 31, December 31,
  2014 2013 2014 2013
         
Collaboration revenue  $ 4,645  $ 3,785  $ 19,231  $ 13,791
         
Operating expenses:        
Research and development 12,571 8,077 43,173 32,785
General and administrative 3,968 3,042 13,632 10,427
         
Total operating expenses 16,539 11,119 56,805 43,212
         
Loss from operations (11,894) (7,334) (37,574) (29,421)
         
Interest and other (expense) income, net 68 17 150 549
Net loss  $ (11,826)  $ (7,317)  $ (37,424)  $ (28,872)
         
Basic and diluted net loss per common share  $ (0.55)  $ (0.43)  $ (1.79)  $ (5.23)
         
Shares used to compute basic and diluted net loss per common share 21,593 16,835 20,865 5,523
         

Amy Kendall, Corporate Communications 415-365-5776

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 32

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 65

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading
Healthcare's Prevention Puzzle Needs Better Incentives

Updated Category News Views 107

When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...

Continue Reading
S&P Global's December 8 Talk Puts Guidance in Focus

Updated Category News Views 54

A 35-minute fireside chat can be a whole lot of nothing, or it can leave a useful breadcrumb trail for shareholders willing to listen closely. S&P Global has put December 8, 2026 on the calendar, when Chief Executive Officer Martina Cheung is scheduled to appear at Goldman Sachs' 2026 Financial Services Conference in New York. Her slot runs from 5:00 p.m. to 5:35 p.m....

Continue Reading
Branch's Fast 500 Rank Signals Payroll Platform Reach

Updated Category News Views 118

Six straight appearances on Deloitte's Fast 500 is not random confetti; it says Branch has kept finding customers while plenty of fintech outfits were busy shrinking their ambitions. The Tampa-based workforce-payments company landed at No. 146 in the 2026 ranking, which measures fiscal-year revenue growth from 2022 through 2025. That is a respectable showing in a list...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 108

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 78

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading
Appian Survey Flags AI Aloneware Maintenance Drag Risk

Updated Category News Views 58

A bot can spit out a feature before lunch, then leave a repair bill nobody budgeted for. That is the uncomfortable issue behind Appian's new research on AI-assisted software development: speed is easy to celebrate, while ownership gets shoved into a dark corner until something breaks. Appian said on November 20, 2026, that two-thirds of surveyed AI decision-makers and IT...

Continue Reading

Top 5 Most Recently Viewed Articles

Lido Staked Ether Experiences Significant Price Fluctuations

Updated Category News Views 50

The Recent Surge in Lido Staked Ether Lido Staked Ether has recently recorded a notable price increase of 3.0% in just the last 24 hours, now trading at $2,344.75. This rise seems to go against its trend over the past week, during which time the asset experienced a slight decline of 1.0%, falling from $2,333.90. The cryptocurrency has impressive highs, having reached an...

Continue Reading
Stella Artois Showcases Friendship with Super Bowl Ad Featuring Icons

Updated Category News Views 665

Stella Artois Presents an Iconic Super Bowl LIX Ad This year, Stella Artois crafts a memorable advertisement for Super Bowl LIX, showcasing the significance of connection through everyday moments. The campaign, titled 'For Moments Worth More,' aims to highlight how the simple pleasures in life can be elevated with the right company and a refreshing Stella Artois lager....

Continue Reading
Glucotrack Appoints New VP to Bolster Regulatory Strategy

Updated Category News Views 229

Glucotrack Welcomes Ted Williams as VP of Regulatory Affairs Glucotrack, Inc. is proud to announce the addition of Ted Williams as the new Vice President of Regulatory Affairs. This strategic move marks a significant step for the company as it continues to innovate and develop solutions for individuals managing diabetes. With nearly 25 years in the industry, Williams...

Continue Reading
Landstar System's Special Dividend Announcement for Shareholders

Updated Category News Views 156

Landstar System, Inc. Declares Special Cash Dividend Recently, Landstar System, Inc. (NASDAQ: LSTR) made headlines with an exciting announcement: a special one-time cash dividend of $2.00 per share. This decision, declared by the Board of Directors on a recent date, reflects the company's robust financial health and commitment to returning value to its shareholders....

Continue Reading
Market Insights: Economic Indicators and Trends to Watch

Updated Category News Views 276

Key Economic Indicators to Watch As we navigate through the current trading landscape, several economic indicators and events are set to shape the market narrative. Understanding these factors is crucial for informed trading decisions. Upcoming Economic Releases Starting the week, we have some pivotal economic releases lined up: Monday's Highlights The week begins with...

Continue Reading